Semma Therapeutics nets $44 mln

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

121 Views

TraceLink rakes in $20 mln

Wakefield, Massachusetts-based TraceLink, a provider of patient safety solutions for life sciences, has closed $20 million in funding. Volition Capital led the round with participation from other investors that included Fidelity Biosciences and FirstMark Capital.

Innovent Biologics grabs $100 mln Series C

Chinese biopharmaceutical firm Innovent Biologics has closed $100 million in Series C funding. Legend Capital led the round with participation from other backers that included Temasek, Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures.

158 Views

Iora Health picks up $28 mln

Cambridge, Massachusetts-based healthcare firm Iora Health has raised $28 million in Series C funding. The investors included Foundation Medical Partners, Rice Management Company, GE Ventures, Khosla Ventures, .406 Ventures, Fidelity Biosciences and Polaris Partners.

136 Views

Regenxbio picks up $30 mln Series C

Regenxbio, a gene therapy biotech firm, has closed $30 million in Series C funding. Venrock and Brookside Capital led the round with participation from others investors that included Deerfield Management, FoxKiser and Fidelity BioSciences. Also, Camille Samuels, a partner at Venrock and Michael Gelman have been added to Regenxbio’s board of directors.

110 Views

Surface Oncology attracts $35 mln Series A

Surface Oncology has secured $35 million in Series A funding. Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates led the round with participation from other investors that included Amgen Ventures and Novartis Institute for Biomedical Research. In addition to the funding, Dr. Elliott Sigal, former head of R&D at Bristol Myers Squibb, has been added to the company’s scientific advisory board. Based in Cambridge, Mass., Surface Oncology is a developer of next-generation cancer immunotherapies.

152 Views

Polaris, Fidelity Biosciences invest $10 mln in Novaerus

Polaris Partners and Fidelity Biosciences have invested $10 million in Novaerus, which works on infection prevention products for nursing homes and assisted living facilities in the U.S. and Europe. Novaerus received a previous investment from Oyster Capital Partners, which will continue to be the majority shareholder in the company.

178 Views

Blueprint Medicines ropes in $50 mln

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.

195 Views

Unum Therapeutics scores $12 mln Series A

Unum Therapeutics has received $12 million in Series A funding. Fidelity Biosciences and Atlas Venture led the round with participation from Sanofi-Genzyme BioVentures. Headquartered in Cambridge, Mass., Unum Therapeutics is developing cellular immunotherapy to treat cancer.

159 Views

Avidity NanoMedicines racks up $6 mln

Avidity NanoMedicines has secured $6 million in convertible note financing. Fidelity Biosciences and TPG Biotech co-led the round. Other investors included Brace Pharmaceuticals, Partner Fund Management and return backer Alethea Capital Management. In addition to the funding, Ben Auspitz from Fidelity Biosciences and Dr. Eran Nadav from TPG Biotech, will be added to Avidity’s board as observers. Based in La Jolla, Calif., Avidity is a maker of drugs that include antibody-siRNA complexes.

128 Views

Aclaris attracts $21 mln Series B

Aclaris Therapeutics said Thursday that it has received $21 million in Series B financing. The investors were return backers Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Based in Malvern, Penn., Aclaris Therapeutics is a specialty pharmaceutical firm focused on developing a treatment that removes various skin lesions.

Netsmart expands board of directors

Netsmart Technologies has added Carl Byers to its board of directors. Byers is a venture partner at Fidelity Biosciences, a unit of Fidelity Investments. Netsmart is a provider of clinical and business software solutions for health and human services organizations.

Coherus BioSciences nabs $55 mln Series C

Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.

Cureatr expands board of directors with new addition

Cureatr, a mobile care coordination solution for healthcare providers, has added Carl Byers to its board of directors. The appointment is effective immediately. Byers is a venture partner at Fidelity Biosciences, a VC fund. Cureatr’s backers include Cardinal Partners, Milestone Venture Partners, JMI Services and the Partnership Fund for New York City.

158 Views

Digital health company Wellframe scores $1.5 mln seed funds

Wellframe has closed $1.5 million in seed funding. The investors included athenahealth CEO Jonathan Bush; Tim Draper, founder and managing director of Draper Fisher Jurvetson; Carl Byers, venture partner at Fidelity Biosciences; and James Nahirny, founder and manager partner at Leerink Capital Partners. Based in Boston, Wellframe is a digital health firm.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget